Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00366717|
Recruitment Status : Completed
First Posted : August 21, 2006
Last Update Posted : August 21, 2006
|Condition or disease|
Despite CMV reactivation has been clearly described in patients underwent transplantation, this phenomenon has not been studied in patients undergoing chemotherapy. Our purpose is to understand if CMV number increases in monocytic leukocytes during chemotherapy and how is the host response to that changes.
Virus load will be studied by quantitative PCR, host response will be studied by measuring patient's anti-CMV IgG, CMV-associated symptoms, serum IFN-r and TNF-a.
|Study Type :||Observational|
|Enrollment :||20 participants|
|Observational Model:||Defined Population|
|Study Start Date :||June 2005|
|Study Completion Date :||January 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00366717
|Mackay Memorial Hospital|
|Taipei, Taiwan, 10449|
|Principal Investigator:||Yen-Ta Lu, MD, PhD.||Mackay Memorial Hospital|